Delivering a new generation of highly selective kinase therapies to dramatically improve patients’ lives

Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development.

Year Invested: 2011
Location: Cambridge, Mass.

Recent News

February 15, 2017
Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference

December 7, 2016
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

December 6, 2016
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

Read More News

Associated Team Members

Alexis Borisy

Neil Exter